Gilead’s $1.7B hep D drug just ran into a roadblock at the FDA

Gilead was following German biotech MYR GmbH and its hepatitis delta virus candidate for “quite some time” before finally pulling the trigger on a $1.7 billion buyout deal. With an EU authorization already under its belt, an OK in the US was all but a done deal — or so...

Click to view original post